Targeted drug combo shows promise for chinese lung cancer patients with BRAF mutation

NCT ID NCT04452877

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of two targeted drugs, dabrafenib and trametinib, in 40 Chinese adults with a specific type of advanced lung cancer (BRAF V600E mutation-positive NSCLC). The goal was to see if the drugs could shrink tumors and control the cancer. Participants received the drugs until their disease worsened or side effects became unacceptable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG

Contacts and locations

Locations

Novartis Investigative Site

Harbin, Heilongjiang, 150081, China
Novartis Investigative Site

Changsha, Hunan, 410013, China
Novartis Investigative Site

Chengdu, Sichuan, 610041, China
Novartis Investigative Site

Hangzhou, Zhejiang, 310003, China
Novartis Investigative Site

Hangzhou, Zhejiang, 310022, China
Novartis Investigative Site

Beijing, 100036, China
Novartis Investigative Site

Guangzhou, 510060, China
Novartis Investigative Site

Shanghai, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.